NCT05949021 - OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 7, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

Triple Negative Breast Cancer (TNBC)

Interventions

DRUG

Combination of liposomal doxorubicin

Combination of liposomal doxorubicin 30 milligrams per square meter and carboplatin (area under the curve 5), administered every 4 weeks for 4 cycles.

Trial Locations (8)

08755

RECRUITING

RWJBarnabas Health - Trinitas hospital and Comprehensive Center, Elizabeth

RECRUITING

RWJBarnabas Health - Community Medical Center, Toms River

07302

RECRUITING

RWJBarnabas Health Jersey City Medical Center, Jersey City

08701

RECRUITING

RWJBarnabas Health - Monmouth Medical Center Southern Campus, Lakewood

08903

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

RECRUITING

RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick

07112

RECRUITING

RWJBarnabas Health - Newark Beth Israel Medical Center, Newark

RECRUITING

University Hospital-Newark, Newark

All Listed Sponsors

lead

Mridula George, MD

OTHER